陈雨意,陈艳红,张勇华,黄尾平,黄克强,许蓓,苏晞

• 1:武汉亚洲心脏病医院心内科

摘要(Abstract)：

目的探讨经皮左心耳封堵术后口服新型口服抗凝药物(NOACs)对器械表面血栓形成和出血事件的影响。方法纳入2014年5月至2016年8月在武汉亚洲心脏病医院心内科接受经皮左心耳封堵术并完成术后45 d门诊随访的患者189例。根据术后不同抗凝方案进行分组:术后口服NOACs进行抗凝治疗者为NOACs组(29例),术后口服华法林进行抗凝治疗者为华法林组(160例)。收集并比较两组患者的临床基线资料、术中资料及术后短期随访资料。结果两组患者年龄、性别、高血压病、卒中史、冠心病史、先天性心脏病、心肌病、心力衰竭、CHA2DS2-VASc评分等基线资料比较,差异均无统计学意义(均P> 0.05);而NOACs组糖尿病比例(34.5%比15.6%,P=0.016)、HAS-BLED评分[(2.3±1.0)分比(1.7±1.2)分,P=0.008]显著高于华法林组,差异均有统计学意义。两组患者封堵器压缩比、成功封堵率、残余分流发生率、残余分流大小、器械表面血栓形成发生率、卒中发生率等术中资料比较,差异均无统计学意义(均P> 0.05)。在术后45 d随访时,两组患者残余分流大小、器械表面血栓形成发生率、缺血性卒中发生率、总出血发生率、脑出血发生率、小出血发生率比较,差异均无统计学意义(均P> 0.05);但NOACs组患者残余分流发生率显著小于华法林组(21.7%比45.4%,P=0.034),差异有统计学意义。结论NOACs用于经皮左心耳封堵术后抗凝治疗,其短期随访不增加器械表面血栓形成及出血事件发生率。

关键词(KeyWords)： 经皮左心耳封堵术;新型口服抗凝药物;华法林;器械表面血栓形成

Abstract:

Keywords:

基金项目(Foundation): 湖北省卫生和计划生育委员会联合基金(WJ2018H0043);; 武汉中青年医学骨干人才培养计划

作者(Author): 陈雨意,陈艳红,张勇华,黄尾平,黄克强,许蓓,苏晞

参考文献(References)：

• [1]Kishore A,Vail A,Majid A,et al.Detection of atrial fibrillation after ischemic stroke or transient ischemic attack:a systematic review and meta-analysis.Stroke,2014,45(2):520-526.
• [2]Flegel KM,Shipley MJ,Rose G.Risk of stroke in non-rheumatic atrial fibrillation.Lancet,1987,1(8532):526-529.
• [3]Stoddard MF,Dawkins PR,Prince CR,et al.Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event:a transesophageal echocardiographic study.J Am Coll Cardiol,1995,25(2):452-459.
• [4]Fauchier L,Cinaud A,Brigadeau F,et al.Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation.J Am Coll Cardiol,2018,71(14):1528-1536.
• [5]Holmes DR,Reddy VY,Turi ZG,et al.Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation:a randomised noninferiority trial.Lancet,2009,374(9689):534-542.
• [6]Bergmann MW,Betts TR,Sievert H,et al.Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendageclosure:three-month data from the EWOLUTIONprospective,multicentre,monitored international WATCHMANLAA closure registry.EuroIntervention,2017,13(7):877-884.
• [7]Lip GY,Hart RG,Conway DS.Antithrombotic therapy for atrial fibrillation.BMJ,2002,325(7371):1022-1025.
• [8]刘新民,董建增.经皮左心耳封堵术.中国医刊,2015,50(10):16-20.
• [9]Giugliano RP,Ruff CT,Braunwald E,et al.Edoxaban versus warfarin in patients with atrial fibrillation.N Engl J Med,2013,369(22):2093-2104.
• [10]Patel MR,Mahaffey KW,Garg J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med,2011,365(10):883-891.
• [11]Granger CB,Alexander JH,McMurray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med,2011,365(11):981-992.
• [12]Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med,2009,361(12):1139-1151.
• [13]Meschia JF,Bushnell C,Boden-Albala B,et al.Guidelines for the primary prevention of stroke:a statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke,2014,45(12):3754-3832.
• [14]Reddy VY,Holmes D,Doshi SK,et al.Safety of percutaneous left atrial appendage closure:results from the Watchman left atrial appendage system for embolic protection in patients with AF(PROTECT AF)clinical trial and the continued access registry.Circulation,2011,123(4):417-424.
• [15]Main ML,Fan D,Reddy VY,et al.Assessment of device-related thrombus and associated clinical outcomes with the WATCHMANleft atrial appendage closure device for embolic protection in patients with atrial fibrillation(from the PROTECT-AF Trial).Am J Cardiol,2016,117(7):1127-1134.
• [16]Lempereur M,Aminian A,Freixa X,et al.Device-associated thrombus formation af ter lef t atrial appendage occlusion:Asystematic review of events reported with the Watchman,the Amplatzer Cardiac Plug and the Amulet.Catheter Cardiovasc Interv,2017,90(5):E111-E121.
• [17]Park JW,Park JW,Sievert H,et al.TCT-86 Results of the Amplatzer cardiac plug European multicenter prospective observational study.J Am Coll Cardiol,2012,60(17):B27.
• [18]Enomoto Y,Gadiyaram VK,Gianni C,et al.Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the watchman device.Heart Rhythm,2017,14(1):19-24.
• [19]Cochet H,Iriart X,Sridi S,et al.Left atrial appendage patency and device-related thrombus after percutaneous left atrial appendage occlusion:a computed tomography study.Eur Heart J Cardiovasc Imaging,2018.[Epub ahead of print]
• [20]Tzikas A,Shakir S,Gafoor S,et al.Left atrial appendage occlusion for stroke prevention in atrial fibrillation:multicentre experience with the AMPLATZER cardiac plug.EuroIntervention,2016,11(10):1170-1179.